AKT1 and cancer: A mechanistically related allosteric inhibitor of compound VIII, MK2206, has been widely used in cancer therapeutic clinical trials aimed to block Akt action (Hirai et al., 2010; Sangai et al., 2012; Yap et al., 2011; Nitulescu et al., 2016).